A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism
ID Number 13-1206Principal Investigator(s)
Department(s) or Division(s)
The proposed project will pilot the use of IGF-1 as a novel treatment for core symptoms of autism. We will use a double-blind, placebo-controlled crossover trial design in five children with autism to evaluate the impact of IGF-1 treatment on autism-specific impairments in socialization, language, and repetitive behaviors. We expect to provide evidence for the safety and feasibility of IGF-1 in ameliorating social withdrawal in children with Autistic Disorder. Further, we expect to demonstrate that IGF-1 is associated with improvement on secondary outcomes of social impairment, language delay, and repetitive behavior, as well as on functional outcomes of global severity. This study will begin recruiting in January 2014.
Recruiting Patients: No